[go: up one dir, main page]

HUP0401648A1 - 6-Hidroxi-izoflavon vegyületek, ezek származékai, valamint ezeket tartalmazó gyógyászati készítmények - Google Patents

6-Hidroxi-izoflavon vegyületek, ezek származékai, valamint ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0401648A1
HUP0401648A1 HU0401648A HUP0401648A HUP0401648A1 HU P0401648 A1 HUP0401648 A1 HU P0401648A1 HU 0401648 A HU0401648 A HU 0401648A HU P0401648 A HUP0401648 A HU P0401648A HU P0401648 A1 HUP0401648 A1 HU P0401648A1
Authority
HU
Hungary
Prior art keywords
alkyl
group
formula
groups
aryl
Prior art date
Application number
HU0401648A
Other languages
English (en)
Inventor
Graham Edmund Kelly
Andrew Heaton
Original Assignee
Novogen Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen Research Pty Ltd filed Critical Novogen Research Pty Ltd
Publication of HUP0401648A1 publication Critical patent/HUP0401648A1/hu
Publication of HUP0401648A3 publication Critical patent/HUP0401648A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

A találmány tárgyát az (I) általános képletű izoflavonszármazékok,ezek gyógyászatilag megfelelő sói vagy prekurzorjai képezik; atalálmány tárgyához tartoznak e vegyületeket tartalmazó gyógyászatikészítmények, valamint a vegyületek előállítására szolgáló eljárásokis. Az (I) általános képletben a szubsztituensek jelentése igensokféle, így például R1 és R2 jelentése lehet például egymástólfüggetlenül hidrogénatom, hidroxilcsoport, -OR9, -CHO, -COOH, alkil-,aril-, aril-alkil-, tio-, alkil-tio-, amino-, alkil-amino-, dialkil-amino-, nitrocsoport vagy halogénatom; továbbá Z0 jelentésehidroxilcsoport vagy R2 jelentése a fentiekben megadott, továbbá R1 ésZ0 a szénatommal együtt, amelyhez kapcsolódnak, 5 tagból álló gyűrűtképeznek (Z-1) és (Z-2) képletű csoportok közül választva, vagy R1jelentése a fentiekben megadottal azonos, és R2 valamint Z0 aszénatomokkal együtt, amelyekhez kapcsolódnak, 5 tagból álló gyűrűtképeznek (Z-3) és (Z-4) képletű csoportok közül választva, továbbá Wjelentése R1, A jelentése hidrogénatom, hidroxilcsoport, -NR3R4 vagytiocsoport, továbbá B jelentése (B-1), (B-2), (B-3) általános képletűcsoportok közül választott, vagy W, A és B azon csoportokkal együtt,amelyekhez kapcsolódnak (W-1), (W-2) és (W-3) képletű csoport közülválasztott, R5 jelentése például -C(O)R11, ahol R11 jelentése példáulalkil- vagy arilcsoport, vagy -CO2R12 képletű csoport, ahol R12jelentése például alkil- vagy arilcsoport; T jelentése egymástólfüggetlenül hidrogénatom, alkil- vagy arilcsoport, X jelentése O, -NR4vagy S, továbbá Y jelentése (Y-1) általános képletű csoport, amelybenR14, R15 es R16 jelentése például egymástól függetlenül hidroxil-, -OR9, -CHO, -COOH, alkil-, halogén-alkil-, aril-, aril-alkil-, tio-,alkil-tio-, amino-, alkil-amino-, dialkil-amino-, nitrocsoport vagyhalogénatom, vagy R14, R15 és R16 közül bármelyik kettő egymássalkondenzálva gyűrűs alkil-, aromás vagy heteroaromás csoportotképezhetnek, és R9 jelentése például alkil- vagy arilcsoport. Atalálmány oltalmi körét számos megkötés, disclaimer korlátozza. Atalálmány szerinti vegyületek előállítása a leírásban bemutatottreakcióvázlatok szerint történik. A találmány szerinti vegyületek ésezeket tartalmazó gyógyászati készítmények eredményesen alkalmazhatókigen sokféle betegség kezelésére, mint például májbetegség,gyulladásos betegségek, psoriázis, burjánzásos betegségek, autoimmunrendellenességek, neurodegeneratív rendellenességek, így Parkinson-kór, Alzheimer-betegség, HIV, koszorúér-betegség, stroke, magasvérnyomás, különböző szembetegségek, mint szürkehályog,makuladegeneráció és így tovább. Ó
HU0401648A 2001-10-25 2002-10-25 6-hydroxy isoflavon compounds, their derivatives and medicaments involving the same HUP0401648A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR8464A AUPR846401A0 (en) 2001-10-25 2001-10-25 6-Hydroxy isoflavones, derivatives and medicaments involving same
PCT/AU2002/001442 WO2003035635A1 (en) 2001-10-25 2002-10-25 6-hydroxy isoflavones, derivatives and medicaments involving same

Publications (2)

Publication Number Publication Date
HUP0401648A1 true HUP0401648A1 (hu) 2004-11-29
HUP0401648A3 HUP0401648A3 (en) 2007-05-29

Family

ID=3832286

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401648A HUP0401648A3 (en) 2001-10-25 2002-10-25 6-hydroxy isoflavon compounds, their derivatives and medicaments involving the same

Country Status (11)

Country Link
US (1) US20050049424A1 (hu)
EP (1) EP1448542A4 (hu)
JP (1) JP2005510503A (hu)
CN (1) CN1575289A (hu)
AU (1) AUPR846401A0 (hu)
CA (1) CA2464593A1 (hu)
HU (1) HUP0401648A3 (hu)
IL (1) IL161517A0 (hu)
MX (1) MXPA04003874A (hu)
NO (1) NO20042084L (hu)
WO (1) WO2003035635A1 (hu)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2136233C (en) 1992-05-19 2004-03-30 Graham Edmund Kelly Health supplements containing phyto-oestrogens, analogues or metabolites thereof
AUPP260798A0 (en) * 1998-03-26 1998-04-23 Novogen Research Pty Ltd Treatment of medical related conditions with isoflavone containing extracts of clover
US20040072765A1 (en) * 1999-04-28 2004-04-15 Novogen Research Pty Ltd. Cardiovascular and bone treatment using isoflavones
AUPQ520300A0 (en) * 2000-01-21 2000-02-17 Novogen Research Pty Ltd Food product and process
EP1794141B1 (en) 2004-09-21 2011-11-09 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
EP1856083A4 (en) * 2005-03-11 2009-05-27 Univ Michigan CHROMENE-4-ON-INHIBITORS OF ANTI-APOPTOTIC MEMBERS OF THE BCL-2 FAMILY AND THEIR USES
DE602006019832D1 (de) * 2005-03-24 2011-03-10 Novogen Res Pty Ltd Isoflavonoiddimere
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2009049214A2 (en) * 2007-10-12 2009-04-16 Northwestern University Inhibition and treatment of prostate cancer metastasis
MY160546A (en) * 2008-07-31 2017-03-15 Sigma Tau Ind Farmaceuti Composition useful for the prevention or reduction of the progression of prostate cancer
WO2010042933A2 (en) * 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
TWI492943B (zh) 2008-12-05 2015-07-21 大塚製藥股份有限公司 喹啉酮化合物及藥學組成物（二）
US9301941B2 (en) * 2009-10-09 2016-04-05 Nestec S. A Methods for preventing or treating sarcopenia and muscle atrophy in animals
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
US9708283B2 (en) 2010-11-01 2017-07-18 Mei Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗
CN104829580B (zh) * 2015-04-11 2017-11-24 云南中烟工业有限责任公司 烟草所含的异黄酮类化合物及其制备方法和应用
US9718799B2 (en) 2015-05-11 2017-08-01 University Of Kentucky Research Foundation 3-aryl-4H-chromene-4-ones as antineoplastic agents for the treatment of cancer
JP6099024B2 (ja) * 2015-05-18 2017-03-22 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤
JP2019513828A (ja) 2016-04-06 2019-05-30 ノクソファーム リミティド 改善された薬物動態を有するイソフラボノイド組成物
CA3058492A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
CN107441079B (zh) * 2017-08-22 2021-03-26 四川省中医药科学院 一种治疗心脑血管疾病的药物及其制备方法和用途
AU2019255310B2 (en) 2018-04-18 2022-11-24 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2020045856A1 (ko) * 2018-08-31 2020-03-05 서울대학교 산학협력단 신규한 HIF-1α 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 안질환의 예방 또는 치료용 약학적 조성물
KR102527205B1 (ko) 2018-08-31 2023-05-03 서울대학교산학협력단 신규한 HIF-1α 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 안질환의 예방 또는 치료용 약학적 조성물
WO2020051644A1 (en) * 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation
CN109925308A (zh) * 2018-12-29 2019-06-25 广东宏盈科技有限公司 异黄酮在制备治疗眼底黄斑病变的药物中的应用
EP4003532B1 (en) 2019-07-24 2024-09-04 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
CN110590738B (zh) * 2019-08-27 2022-03-01 温州大学 一种3,6-二甲基-1-仲胺基-7-氰基-8-羟基异喹啉类化合物的合成方法
WO2021195698A1 (en) * 2020-03-30 2021-10-07 Noxopharm Limited Methods for the treatment of inflammation associated with infection
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CN117384124B (zh) * 2022-07-04 2025-08-01 安徽中医药大学 Hdac抑制剂、组合物及其应用
WO2025023252A1 (ja) * 2023-07-24 2025-01-30 国立大学法人 大分大学 抗酸化化合物
CN118373794B (zh) * 2024-04-17 2025-08-29 中国中医科学院中药研究所 一种异黄酮类化合物及其制备方法和在制药中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264509A (en) * 1977-06-08 1981-04-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
CA2136233C (en) * 1992-05-19 2004-03-30 Graham Edmund Kelly Health supplements containing phyto-oestrogens, analogues or metabolites thereof
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
GB9621757D0 (en) * 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US6146668A (en) * 1997-04-28 2000-11-14 Novogen, Inc. Preparation of isoflavones from legumes
EP0979074A4 (en) * 1997-05-01 2003-07-09 Novogen Inc TREATMENT OR PREVENTION CLIMATE ACTION SYMPTOMS AND OSTEOPOROSIS
WO1999049862A1 (en) * 1998-03-30 1999-10-07 The University Of Mississippi Isoflavones for treating giardiasis and malaria
AUPQ008299A0 (en) * 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
FI20001593A7 (fi) * 2000-07-03 2002-01-04 Orion Yhtymo Oyj Comt-entsyymiõ inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
JP4256679B2 (ja) * 2001-03-16 2009-04-22 ノボゲン リサーチ ピーティーワイ リミテッド 再狭窄の治療方法

Also Published As

Publication number Publication date
AUPR846401A0 (en) 2001-11-15
CA2464593A1 (en) 2003-05-01
WO2003035635A1 (en) 2003-05-01
JP2005510503A (ja) 2005-04-21
HUP0401648A3 (en) 2007-05-29
CN1575289A (zh) 2005-02-02
EP1448542A4 (en) 2005-11-16
EP1448542A1 (en) 2004-08-25
NO20042084L (no) 2004-05-21
IL161517A0 (en) 2004-09-27
US20050049424A1 (en) 2005-03-03
MXPA04003874A (es) 2004-07-16

Similar Documents

Publication Publication Date Title
HUP0401648A1 (hu) 6-Hidroxi-izoflavon vegyületek, ezek származékai, valamint ezeket tartalmazó gyógyászati készítmények
ATE367809T1 (de) Cannabinoiden als antioxidantien und neuroschützende mittel
HUP0303164A2 (hu) Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények
RU2006139030A (ru) Ингибиторы gsk-3
HUP0401982A2 (hu) Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
UY28339A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
DK1583524T3 (da) Bis(thiohydrazidamid)-forbindelser til behandling af multilægemiddel-resistent cancer
MEP58808A (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
HUP0200310A2 (hu) Triciklikus pirazolszármazékok alkalmazása gyógyszerkészítmények előállítására és az új vegyületek
HUP0400743A2 (hu) Imidazo[1,5-a]pirimido[5,4-d]benzazepin-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP0202578A2 (hu) Flavonok, xantonok és kumarinok új származékai
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
Okombo et al. Antischistosomal activity of pyrido [1, 2-a] benzimidazole derivatives and correlation with inhibition of β-hematin formation
ATE157966T1 (de) 22-oxacholecalziferol-derivate und ihre herstellung
DE60132032D1 (de) Benzoxazol-Derivative, Verfahren zu ihrer Herstellung und Herbizide
HUP0202581A2 (hu) Kalkon-kumarinok
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
HUT55784A (en) New 1-oxa-2-oxo-8-aza-spiro (4,5) decane derivatives and process for producing them
ATE291568T1 (de) Herstellung von tamiflu über das zwischenprodukt gallocarbonsäure
CA2403188A1 (en) Pyridazinyl phenyl hydrazones useful against congestive heart failure
EA200870492A1 (ru) N-оксиды производных пиридилметилпиперазина и - пиперидина
EP1803808A4 (en) Lecithinized superoxide dismutase composition and process for producing the same
ATE226196T1 (de) Neue cyclische aminophenylessigsäurederivate, ihre herstellung und immunomodulatoren , welche diese als aktiven bestandteil enthalten
ES2568470T3 (es) Derivados aromáticos bicíclicos de sulfinil
MXPA04005838A (es) Nuevos compuestos de benzotiazina y benzotiadiazina un proceso para su prepacion y las composiciones farmaceuticas que los contienen.